ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας ξγεεηϊ ςμ δϊεφΰεϊ μψαςεο δωπι ωμ 2006 ξςμδ ΰϊ δϊηζιϊ μωπϊ 200608/08/2006
δξλιψεϊ αψαςεο ςμε α- 77% εδρϊλξε α- 2,172 ξμιεο $
ψεεη πχι ωμ 488 ξμιεο $ εψεεη πχι μξπιδ αγιμεμ ξμΰ ωμ 0.59$ δλεμμιν δεφΰεϊ ξρειξεϊ
ψεεη πχι ξεϊΰν μψαςεο δωπι (μτπι δεφΰεϊ ξρειξεϊ)* ωμ 541 ξμιεο $, βιγεμ ωμ 124%, εψεεη μξπιδ ξεϊΰν* αγιμεμ ξμΰ ωμ 0.66$, βιγεμ ωμ 83%
δϊεφΰεϊ λεμμεϊ μψΰωεπδ ψαςεο ξμΰ ωμ IVAX
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ γιεεηδ διεν ςμ ϊεφΰεϊ δψαςεο δωπι ωδρϊιιν α- 30 αιεπι, 2006, δψαςεο δψΰωεο ΰωψ λεμμ ϊεφΰεϊ ωμ ψαςεο ξμΰ ωμ IVAX ξΰζ δωμξϊ ψλιωϊ IVAX α- 26 αιπεΰψ, 2006.
δϊεφΰεϊ ωμ δψαςεο δωπι, ςμ τι λμμι ηωαεπΰεϊ ξχεαμιν αΰψδ"α (US GAAP), δλεμμεϊ 31 ξμιεο $ αβιο ωιςψεκ ξμΰι δχωεψ μψλιωϊ IVAX, 22 ξμιεο $ αβιο δτηϊϊ ζλειεϊ ξεφψ ε- 12 ξμιεο $ αβιο ψδ-ΰψβεο, ιψιγϊ ςψκ ωμ πλριν χαεςιν εξε"τ αϊδμικ αηαψεϊ χωεψεϊ, δρϊλξε αψεεη πχι ωμ 488 ξμιεο $ ΰε ψεεη πχι μξπιδ αγιμεμ ξμΰ ωμ 0.59$. θας ξΰξιπδ λι δφβϊ πϊεπιν μτπι δεφΰεϊ ΰμε, ξωχτϊ πλεο ιεϊψ ΰϊ δξβξεϊ ατςιμεϊ δηαψδ. ψεεη πχι ξεϊΰν* μψαςεο δωπι δρϊλν α- 541 ξμιεο $, βιγεμ ωμ 124% μςεξϊ δψαςεο δξχαιμ ΰωϊχγ εψεεη μξπιδ ξεϊΰν* αγιμεμ ξμΰ, δρϊλν α- 0.66$, βιγεμ ωμ 83% αδωεεΰδ μ- 0.36$ αψαςεο δξχαιμ ΰωϊχγ.
ιωψΰμ ξχεα, πωιΰ εξπλ"μ θας, δβια ςμ δϊεφΰεϊ: "διδ ζδ ψαςεο αεμθ εξψϊχ ςαεψ θας ζδε ψαςεο ωιΰ δο αϊεφΰεϊ δτιππριεϊ εδο αδιωβιν δΰρθψθβιιν. διδμεν αλϊψ διϊδ δδωχδ δξεφμηϊ αξιεηγ ωμ simvastatin, ΰωψ διπδ δδωχδ δβγεμδ αιεϊψ αδιρθεψιδ ωμ δϊςωιιδ δβπψιϊ. δωχδ ζε, λξε ωΰψ διωβπε αψαςεο ζδ, ξαθΰιν ΰϊ δξεγμ δςρχι δξεφμη ωμ θας, ΰϊ ςεφξϊδ εβξιωεϊδ ωμ ωψωψϊ δΰρτχδ δβμεαμιϊ, ωΰιο ωπι μδ αϊςωιιδ εΰϊ ξφειπεϊιπε ααιφες δΰρθψθβιδ ωμπε. θας ςψελδ διθα μδξωικ εμξπσ ΰϊ ηεζχεϊιδ εμπφμ ΰϊ δδζγξπειεϊ εδΰϊβψιν δπεαςιν ξδραιαδ δςρχιϊ δγιπξιϊ αδ διΰ τεςμϊ."
ξψ ξχεα δερισ: "λξε λο δφβπε δϊχγξεϊ ξψωιξδ αϊδμικ δΰιπθβψφιδ ςν IVAX, ΰωψ ξϊχγν αξδιψεϊ ωιΰ. μξςωδ, ΰπηπε πδπιν λαψ λςϊ ξτιψεϊ ψλιωϊ IVAX, ΰωψ ξεριτδ μψεεη μξπιδ ((accretive λαψ αψαςεο ζδ εφτειδ μδξωικ μδιεϊ λκ αξδμκ δωπδ λεμδ εμΰηψιδ."
δξλιψεϊ πθε αψαςεο δωπι βγμε α- 77% αδωεεΰδ μψαςεο δξχαιμ ΰωϊχγ εδρϊλξε α- 2,172 ξμιεο $. δωχϊν ωμ ξεφψιν ηγωιν αΰψδ"α εδλμμϊο ωμ ξλιψεϊ IVAX, ΰωψ ϊψξε μλμ δωεεχιν αςεμν, διε ριαεϊ δςιχψιεϊ μβιγεμ ζδ.
δξλιψεϊ αφτεο ΰξψιχδ διεε 62% ξλμμ ξλιψεϊ δηαψδ, λΰωψ ΰιψετδ διεεϊδ 24%, εξλιψεϊ αιπμΰεξιεϊ (αςιχψ ΰξψιχδ δμθιπιϊ, ξψλζ εξζψη ΰιψετδ ειωψΰμ) διεε 14%.
δξλιψεϊ δτψξφαθιεϊ αφτεο ΰξψιχδ (λεμμ χετχρεο®) δρϊλξε α- 1,227 ξμιεο $ αψαςεο, αδωεεΰδ μ- 624 ξμιεο $ αψαςεο δωπι ωμ 2005, βιγεμ ωμ 97%. δξλιψεϊ δεωτςε μθεαδ αψαςεο δωπι ξδωχϊν ωμ 7 ξεφψιν ηγωιν αΰψδ"α, λωδςιχψιιν αιπιδν δν simvastatin ε- pravastatin, ξδλμμϊν ωμ ςεγ 19 ξεφψιν ηγωιν ωμΰ πξλψε αψαςεο δξχαιμ ΰωϊχγ, εξβιγεμ αξλιψεϊ δχετχρεο®.
πλεο μ- 1 αΰεβερθ, 2006, μθας 148 αχωεϊ δξξϊιπεϊ μΰιωεψ ρετι ωμ ψωεϊ δξζεο εδϊψετεϊ δΰξψιχΰιϊ (FDA). ρκ δξλιψεϊ δωπϊιεϊ ωμ αχωεϊ ΰμδ, αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, διπε λ- 84 ξμιΰψγ $. θας ξΰξιπδ λι διπδ δψΰωεπδ μδβιω αχωδ μΰιωεψ ςαεψ 46 ξεφψιν ξϊεκ αχωεϊ ΰμδ, δξωχτιν αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, ξςμ μ- 35 ξμιΰψγ $.
δξλιψεϊ δτψξφαθιεϊ αΰιψετδ (λεμμ χετχρεο®) βγμε α- 41% αψαςεο εδρϊλξε α- 491 ξμιεο $. απερσ μψλιωδ ωμ IVAX, δβιγεμ πεας ξξλιψεϊ βπψιεϊ βαεδεϊ ιεϊψ (δλεμμεϊ ΰϊ δωχϊν ωμ 38 ξεφψιν α- 9 ωεεχιν ωεπιν αψαςεο) εξβιγεμ αξλιψεϊ δχετχρεο®.
ξλιψεϊ τψξφαθιεϊ αιπμΰεξιεϊ, δλεμμεϊ αςιχψ ΰϊ ΰξψιχδ δμθιπιϊ, ξγιπεϊ ξψλζ εξζψη ΰιψετδ ειωψΰμ, βγμε δψαςεο α- 120% εδρϊλξε α- 265 ξμιεο $. δβιγεμ πεας ξδερτδ ωμ ωεεχιν ηγωιν εξδψηαϊ δξλιψεϊ αωεεχιν δχιιξιν αΰξψιχδ δμθιπιϊ εαξψλζ εξζψη ΰιψετδ, λϊεφΰδ ξψλιωϊ IVAX.
χετχρεο® - δξλιψεϊ δβμεαμιεϊ ωμ χετχρεο®, αξεπηι ξηιψ ξλιψδ μωεχ, δρϊλξε αψαςεο ζδ α- 353 ξμιεο $, βιγεμ ωμ 22% αδωεεΰδ μψαςεο δξχαιμ α- 2005, ελκ τςν περτϊ, δχετχρεο® διδ δξεφψ αςμ ωιςεψ δφξιηδ δβαεδ αιεϊψ αωεχ δθψωϊ δπτεφδ (MS) δςεμξι. δξλιψεϊ αΰψδ"α αξεπηι ξηιψ ξλιψδ μωεχ αψαςεο δωπι βγμε α- 19% εδρϊλξε α- 231 ξμιεο $. δξλιψεϊ αξεπηι ξηιψ ξλιψδ μωεχ ξηευ μΰψδ"α, αςιχψ αΰιψετδ εχπγδ, βγμε α- 26% εδρϊλξε α- 123 ξμιεο $. μτι πϊεπι δ- IMS, αΰψδ"α, χετχρεο® δξωικ μηζχ ΰϊ ξςξγε λξεαιμ αωεχ εδβις μπϊη ωεχ ωμ 33.9% ξρκ λμ δξψωξιν αΰψδ"α (TRx) ε- 34.9% αξεπηι ξψωξιν ηγωιν (NRx) αηεγω ιεπι 2006.
®Azilect - αιεμι 2006, ®Azilect (θαμιεϊ rasagiline), δθιτεμ ωμ θας μξημϊ δτψχιπρεο, δπιϊο αξιπεο ωμ τςν αιεν, εδξεφψ διιηεγι δωπι ωμδ, δεϊψ μωιεεχ αΰψδ"α. δξεφψ ξωεεχ ςμ-ιγι ηαψϊ δαϊ ωμ θας ΰψδ"α μωιεεχ ξεφψιν ιηεγιιν, Teva Neuroscience, Inc. λιεν, ®Azilect, δξεϊεεδ μθιτεμ αϊρξιπιν ωμ ξημϊ τψχιπρεο ΰιγιετθιϊ (ξξχεψ μΰ ιγες) λθιτεμ ιηιγπι δϊημϊι ΰε λθιτεμ ξωεμα ςν levodopa, ξεϊψ μωιξεω α- 16 ξγιπεϊ.
ξλιψεϊ δλιξιδ (API) λεμμ ξλιψεϊ τπιξιεϊ μςρχιδ δτψξφαθιιν ωμ θας, δρϊλξε α- 355 ξμιεο $, βιγεμ ωμ 41% μςεξϊ δψαςεο δωπι α- 2005. ξλιψεϊ δ- API μφγγιν ωμιωιιν δρϊλξε α- 145 ξμιεο $, βιγεμ ωμ 14% μςεξϊ δψαςεο δξχαιμ ΰωϊχγ. ςιχψ δβιγεμ αξλιψεϊ τπιξιεϊ ξωχσ δψηαδ ωμ δΰιπθβψφιδ δΰπλιϊ ωμπε.
ωιςεψ δψεεη δβεμξι δξεϊΰν (μΰηψ πιθψεμ δωιςψεκ ωμ δξμΰι ωμ IVAX ωδβγιμ ΰϊ ςμεϊ δξλψ) δβις μ- 55.4% αψαςεο δωπι ωμ 2006 αδωεεΰδ μωιςεψ ψεεη βεμξι ωμ 47.4% αψαςεο δωπι ωμ 2005 εωμ 47.2% αωπϊ 2005 λεμδ. ωιςεψ ψεεη βεμξι ζδ, δβαεδ αΰετο ιεφΰ γετο, ξωχσ ΰϊ δξηζεψ δπιλψ ωμ δωχεϊ ξεφψιν αψαςεο ζδ αΰψδ"α, δξξεζβεϊ ΰπλιϊ, λΰωψ δβγεμδ ωαδν διϊδ simvastatin.
δεφΰεϊ ξηχψ ετιϊεη (ξε"τ) πθε βγμε α- 33% εδβιςε μωιΰ ψαςεπι ωμ 121 ξμιεο $.
δεφΰεϊ ξλιψδ, δπδμδ ελμμιεϊ (SG&A) διεε 17.3% ξδξλιψεϊ πθε εδρϊλξε α- 376 ξμιεο $ αδωεεΰδ μ- 14.9% ξρκ δξλιψεϊ πθε ε- 183 ξμιεο $ αψαςεο δωπι ωμ 2005. ψξεϊ βαεδεϊ ΰμδ ξωχτεϊ ΰϊ δβγμϊ δτςιμεϊ αϊηεν ϊψετεϊ δξεϊβ εαωεεχιν δξΰετιιπιν αβπψιχδ ξξεϊβϊ αϊξδιμ δπεληι ωμ θας, δπεας αςιχψ ξψλιωϊ IVAX, δξΰετιιπϊ αψξεϊ βαεδεϊ ιεϊψ ωμ δεφΰεϊ SG&A. δεφΰεϊ SG&A λμμε βν ψιωεν ωμ δεφΰεϊ αβιο ΰετφιεϊ μςεαγιν ωδρϊλξε αλ- 1 ρπθ μξπιδ.
ωιςεψ δξρ ωπχας αψαςεο ζδ δεΰ 16.7%. ωιςεψ ζδ ξηεωα ςμ τι ωιςεψ ξρ ωπϊι ωμ- 17.5%, δξωχσ ΰϊ δςψλϊπε δπεληιϊ δθεαδ αιεϊψ μβαι ωπϊ 2006 λεμδ, αδωεεΰδ μ- 18% αωπϊ 2005.
ϊζψιν δξζεξπιν ξτςιμεϊ ωεθτϊ αψαςεο δωπι ωμ 2006 δρϊλν α- 212 ξμιεο $, ϊζψιν αςμ ηωιαεϊ, αδϊηωα αιϊψϊ δμχεηεϊ δβαεδδ αψαςεο ζδ λϊεφΰδ ξδωχεϊ βγεμεϊ αΰψδ"α. ωεει ξζεξπιν επιιψεϊ ςψκ ρηιψιν μιεν 30 αιεπι, 2006 διδ 1.65 ξμιΰψγ $.
δδεο δςφξι ωμ θας δρϊλν α- 30 αιεπι, 2006, α- 9.9 ξμιΰψγ $, βιγεμ ωμ 0.7 ξμιΰψγ $ μςεξϊ 31 αξψυ, 2006 αςιχψ λϊεφΰδ ξδψεεη αψαςεο.
ξρτψ δξπιεϊ - πλεο μψαςεο δωπι ωμ 2006, ξρτψ δξπιεϊ μφεψκ ηιωεα δψεεη δπχι μξπιδ αγιμεμ ξμΰ, διπε 833.9 ξμιεο ξπιεϊ.
ϊηζιϊ μωπϊ 2006 δηαψδ φετδ λι ξλιψεϊιδ μωπϊ 2006 ιρϊλξε αλ- 8.5 ξμιΰψγ $. δηαψδ ξςμδ ΰϊ φιτιεϊιδ δχεγξεϊ μψεεη μξπιδ ξεϊΰν μωπϊ 2006 (μτπι ρςιτιν ξρειξιν) αγιμεμ ξμΰ ξθεεη ωμ 2.15$ - 2.02$ (λεμμ αμςγιεϊ ωμ (simvastatin μθεεη ωμ 2.25$ - 2.15$.
γιαιγπγ
γιψχθεψιεο δηαψδ, αιωιαϊε ξιεν 7 αΰεβερθ, 2006, δλψιζ ςμ ϊωμεν γιαιγπγ αξζεξο αβιο δψαςεο δωπι ωμ ωπϊ 2006, αωιςεψ ωμ 0.34 ω"η μξπιδ (λ- 7.7 ρπθ ςμ τι ωςψ δγεμψ α- 7 αΰεβερθ, 2006). διεν δχεας ιδιδ α- 15 αΰεβερθ, 2006 (ιεν δΰχρ ιδιδ α- 16 αΰεβερθ, 2006), ειεν δϊωμεν πχας μ- 31 αΰεβερθ, 2006. ωιςεψ δξρ ωιπελδ αξχεψ ιδιδ 16%.
πτψθι ωιηϊ δεςιγδ
δπδμϊ θας ϊχιιν ωιηϊ εςιγδ αιεν ωμιωι, 8 αΰεβερθ, 2006, αωςδ 15:45 ωςεο ιωψΰμ (08:45 ωςεο πιε-ιεψχ) ΰωψ αδ ιιρχψε ϊεφΰεϊ δψαςεο δωπι ωμ 2006. πιϊο μδΰζιο μωιηδ γψκ ΰϊψ δΰιπθψπθ ωμ θας, αλϊεαϊ : www.tevapharm.com. πιϊο ιδιδ μδΰζιο μωιγεψ ηεζψ ςγ μιεν 15 αΰεβερθ, 2006 αηφεϊ (ωςεο πιε-ιεψχ) αΰϊψ δηαψδ, ΰε ςμ-ιγι ηιεβ 1-877-660-6853 μξηιιβιν αϊεκ ΰψδ"α ε- 201-612-7415 μξηιιβιν ξηευ μΰψδ"α. χεγ δλπιρδ μωιγεψ δηεζψ διπε ηωαεο ξρτψ (Account #) 3055 ε- ϊε δζιδει (ID#) διπε: 209542.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ- 20 δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ, ιιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ εξεφψιν εεθψιπψιν, διπδ δηαψδ δξεαιμδ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο εαξψλζ ΰξψιχδ εαΰιψετδ. ιεϊψ ξ- 80% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ.
μδμο δρςισ διγες αΰψδ"α λ- Safe Harbor απερηε δΰπβμι εΰωψ ξθψϊε μδβο ςμ δηαψδ, ςτ"ι δγιο δΰξψιχΰι:
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |